116 results on '"Lin, Yu-Hsi"'
Search Results
2. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment
3. A cyclic dipeptide for salinity stress alleviation and the trophic flexibility of an endophyte reveal niches in salt marsh plant-microbe interactions
4. An enolase inhibitor for the targeted treatment of ENO1-deleted cancers
5. Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine
6. Impaired anaplerosis is a major contributor to glycolysis inhibitor toxicity in glioma
7. An inhibitor of oxidative phosphorylation exploits cancer vulnerability
8. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer
9. Hyperbolicity study of the modulation equations for the Benjamin–Bona–Mahony equation
10. Anaplerotic nutrient stress drives synergy of angiogenesis inhibitors with therapeutics targeting tumor metabolism
11. Turbulence Kinetic Energy inside Suspended Vegetation Domain under Periodic Water Waves
12. Abstract 3097: Prodrugs of a 1-hydroxy-2-oxopiperidin-3-yl phosphonate enolase inhibitor for the treatment of ENO1-deleted cancers
13. Supplementary Figures S1-S4 from A Novel B7-H6–Targeted IgG-Like T Cell–Engaging Antibody for the Treatment of Gastrointestinal Tumors
14. Comparative Pharmacology of a Bis-Pivaloyloxymethyl Phosphonate Prodrug Inhibitor of Enolase after Oral and Parenteral Administration
15. Author Correction: An enolase inhibitor for the targeted treatment of ENO1-deleted cancers
16. NAD+ biosynthesis as a collateral lethality target for precision oncology
17. Prodrugs of a 1-Hydroxy-2-oxopiperidin-3-yl Phosphonate Enolase Inhibitor for the Treatment of ENO1-Deleted Cancers
18. A Novel B7-H6–Targeted IgG-Like T Cell–Engaging Antibody for the Treatment of Gastrointestinal Tumors
19. An empirical model for predicting wave attenuation inside vegetation domain
20. Abstract 3208: Angiogenesis inhibitors strongly synergize with therapeutics targeting tumor metabolism
21. Targeting Host Glycolysis as a Strategy for Antimalarial Development
22. Additional file 1 of Impaired anaplerosis is a major contributor to glycolysis inhibitor toxicity in glioma
23. Correspondence to "Oral immunotherapy in alpha‐gal red meat allergy: Could specific IgE be a potential biomarker in monitoring management?".
24. Introduction and Application of a Simple Probabilistic Liquefaction Hazard Analysis Program: HAZ45PL Module
25. Author Correction: An enolase inhibitor for the targeted treatment of ENO1-deleted cancers
26. Impaired Anaplerosis Is a Major Contributor to Glycolysis Inhibitor Toxicity in Glioma
27. TAMI-62. ANGIOGENESIS INHIBITORS STRONGLY SYNERGIZE WITH THERAPEUTICS TARGETING TUMOR METABOLISM
28. Targeting host glycolysis as a strategy for antimalarial development
29. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma
30. KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer
31. Methylthioadenosine is Not Dramatically Elevated inMTAP-Homozygous Deleted Primary Glioblastomas
32. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF signaling in KMT2D Mutant Melanoma
33. First Experimental Demonstration and Mechanism of Abnormal Palladium Diffusion Induced by Excess Interstitial Ge
34. Author Correction: Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer
35. Abstract 2831: Collateral lethality: A new target for personalized oncology
36. Eradication of ENO1-deleted Glioblastoma through Collateral Lethality
37. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment
38. TMIC-22. DECIPHERING GLIOMA INTRINSIC TRANSCRIPTIONAL SUBTYPES IDENTIFIES TUMOR EVOLUTION ASSOCIATES WITH CHANGES IN IMMUNE-MICROENVIRONMENT
39. Abstract A39: Pomhex, a cell-permeable high potency enolase inhibitor with utility for collateral lethality treatment of cancer
40. ENOblock Does Not Inhibit the Activity of the Glycolytic Enzyme Enolase
41. TMIC-14. TUMOR EVOLUTION OF GLIOMA INTRINSIC GENE EXPRESSION SUBTYPE ASSOCIATES WITH IMMUNOLOGICAL CHANGES IN THE MICROENVIRONMENT
42. SF2312 is a natural phosphonate inhibitor of enolase
43. Combination of JAK2 and HSP90 inhibitors: an effective therapeutic option in drug-resistant chronic myelogenous leukemia
44. Abstract 4242: Rhodamine esters as fluorescent tumor painting agents for glioblastoma
45. Abstract 3837: Passenger deletion of ENO1 as a collateral lethality target in cancer
46. Tumor evolution of glioma intrinsic gene expression subtype associates with immunological changes in the microenvironment
47. Abstract C183: Pomhex: a cell-permeable high potency Enolase inhibitor with in vivo anti-neoplastic activity
48. MTR-19A MACROPHAGE-/MICROGLIAL-RICH TUMOR MICROENVIRONMENT MIMICS PRONEURAL TO MESENCHYMAL TRANSITION IN GLIOBLASTOMA
49. Adaptation and health among first-generation Taiwanese Americans
50. Social support of married persons in the United States and Italy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.